High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Miró, J.M.; Entenza, J.M.; Del Río, A.; Velasco, M.; Castañeda, X.; Garcia de la Mària, C.; Giddey, M.; Armero, Y.; Pericàs, J.M.; Cervera, C.; Mestres, C.A.; Almela, M.; Falces, C.; Marco, F.; Moreillon, P.; Moreno, A.

doi:10.1128/AAC.06449-11

High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Détails

Demande d'une copie

ID Serval

serval:BIB_7B56DF392269

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Périodique

Antimicrobial Agents and Chemotherapy

Auteur⸱e⸱s

Miró J.M., Entenza J.M., Del Río A., Velasco M., Castañeda X., Garcia de la Mària C., Giddey M., Armero Y., Pericàs J.M., Cervera C., Mestres C.A., Almela M., Falces C., Marco F., Moreillon P., Moreno A.

Collaborateur⸱rice⸱s

Hospital Clinic Experimental Endocarditis Study Group

Contributeur⸱rice⸱s

Miró JM., Moreno A., del Río A., Cervera C., Pericas JM., Castañeda X., Gatell JM., Marco F., Garcia de la Mària C., Armero Y., Almela M., Jiménez-de-Anta MT., Mestres CA., Paré JC., Falces C., Cartañá£££Ramón£££ R. , Ninot S., Azqueta M., Sitges M., Heras M., Pomar JL., Ramírez J., Ribalta T., Brunet M., Soy D., Perez I.

ISSN

1098-6596 (Electronic)

ISSN-L

0066-4804

Statut éditorial

Publié

Date de publication

2012

Peer-reviewed

Oui

Volume

Numéro

Pages

4511-4515

Langue

anglais

Notes

Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Résumé

We describe 3 patients with left-sided staphylococcal endocarditis (1 with methicillin-susceptible Staphylococcus aureus [MSSA] prosthetic aortic valve endocarditis and 2 with methicillin-resistant S. aureus [MRSA] native-valve endocarditis) who were successfully treated with high-dose intravenous daptomycin (10 mg/kg/day) plus fosfomycin (2 g every 6 h) for 6 weeks. This combination was tested in vitro against 7 MSSA, 5 MRSA, and 2 intermediately glycopeptide-resistant S. aureus isolates and proved to be synergistic against 11 (79%) strains and bactericidal against 8 (57%) strains. This combination deserves further clinical study.

Mots-clé

Aged, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/adverse effects, Daptomycin/administration & dosage, Daptomycin/adverse effects, Drug Synergism, Drug Therapy, Combination, Endocarditis, Bacterial/drug therapy, Female, Fosfomycin/administration & dosage, Fosfomycin/adverse effects, Humans, Male, Methicillin-Resistant Staphylococcus aureus/drug effects, Microbial Sensitivity Tests, Middle Aged, Staphylococcal Infections/drug therapy, Staphylococcal Infections/microbiology

OAI-PMH

oai:serval.unil.ch:BIB_7B56DF392269

DOI

10.1128/AAC.06449-11

Pubmed

22644033

Web of science

000306826300066

Open Access

Oui

Création de la notice

01/11/2012 19:44